Table 1 Baseline characteristics of high-risk and non-high-risk individuals (safety analysis set)

From: Blood pressure-lowering effects of nifedipine/candesartan combinations in high-risk individuals: subgroup analysis of the DISTINCT randomised trial

Characteristic

Renal impairment of any grade (baseline eGFR<90  ml min−1)

T2DM

Hypercholesterolaemia (total cholesterol >240 mg dl−1)

CV risk factor(s) (T2DM or BMI30 kg m−2 or LDL130 mg dl−1)

 

Yes (N=426)

No (N=955)

Yes (N=205)

No (N=1176)

>240 (N=210)

200–240 (N=454)

<200 (N=715)

1–3 (N=986)

1–2 (N=958)

1 (N=679)

None (N=395)

Age, years, mean

61.6

50.6

56.8

53.5

55.2

54.0

53.7

53.7

53.7

53.4

54.8

Male, n (%)

232 (54.5%)

567 (59.4%)

116 (56.6%)

683 (58.1%)

110 (52.4%)

245 (54.0%)

442 (61.8%)

547 (55.5%)

534 (55.7%)

390 (57.4%)

252 (63.8%)

Ethnicity

 White, n (%)

317 (74.4%)

685 (71.7%)

148 (72.2%)

854 (72.6%)

166 (79.0%)

353 (77.8%)

481 (67.3%)

730 (74.0%)

712 (74.3%)

494 (72.8%)

272 (68.9%)

 Black, n (%)

46 (10.8%)

180 (18.8%)

33 (16.1%)

193 (16.4%)

25 (11.9%)

59 (13.0%)

142 (19.9%)

180 (18.3%)

173 (18.1%)

121 (17.8%)

46 (11.6%)

 Asian, n (%)

55 (12.9%)

68 (7.1%)

11 (5.4%)

112 (9.5%)

14 (6.7%)

35 (7.7%)

74 (10.3%)

55 (5.6%)

53 (5.5%)

48 (7.1%)

68 (17.2%)

BMI, kg m−2, mean

27.4

32.6

32.3

30.8

30.4

31.2

31.1

32.9

32.8

32.2

26.2

Obesity (BMI30 kg m−2), n (%)

109 (25.6%)

619 (64.8%)

129 (62.9%)

599 (50.9%)

97 (46.2%)

242 (53.3%)

389 (54.4%)

728 (73.8%)

700 (73.1%)

437 (64.4%)

393 (99.5%)

SBP, mm Hg, mean

158.8

155.5

159.1

156.1

157.1

156.3

156.5

156.3

156.3

156.1

157.1

DBP, mm Hg, mean

99.3

99.7

99.3

99.6

99.2

99.9

99.4

99.5

99.5

99.5

99.6

  1. Abbreviations: BMI, body mass index; CV, cardiovascular; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; LDL, low-density lipoprotein; SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus.